Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine Search
Americas
There were no surprises, but plenty of alarms yesterday following the US Court of Appeals for the Federal Circuit’s decision to reject Sequenom’s request for a re-hearing of its dispute with Ariosa Diagnostics en banc.   3 December 2015
Sequenom’s en banc petition rejected by Federal Circuit
Americas
The US Court of Appeals for the Federal Circuit has rejected Sequenom’s petition to re-hear its dispute with Ariosa Diagnostics en banc.   2 December 2015
Bass strikes again, targets anaesthetic drug in IPR
Big Pharma
Hedge fund manager Kyle Bass has filed another inter partes review, teaming up with Erich Spangenberg, the former head of patent monetisation firm IPNav, for a second time.   2 December 2015
Medtech
The US Supreme Court has rejected both Nautilus’s and Covidien’s attempt to reverse patent infringement judgments in two separate disputes centring on medical devices.   1 December 2015
Americas
A group of technology companies has urged the US Supreme Court to re-hear the Nautilus v Biosig case, arguing that the US Court of Appeals for the Federal Circuit failed to apply the “reasonable certainty” standard for determining whether a patent claim is indefinite.   30 November 2015
Asia-Pacific
Indian pharmaceutical company Dr Reddy’s has agreed a deal to buy global intellectual property rights to a generic version of GSK’s deep vein thrombosis treatment Arixtra (fondaparinux sodium) as part of a $17.5 million deal with a partner company.   27 November 2015
Big Pharma
The English High Court has rejected Pfizer’s attempt to amend a patent that was ruled partially invalid in its long-standing dispute with generics companies Mylan and Allergan.   26 November 2015
Americas
Hedge fund manager Kyle Bass has requested that the Patent and Trial and Appeal Board review the validity of a patent owned by Alpex Pharma.   25 November 2015
Africa
Authorities in Kenya have destroyed more than 65,000 kilos of counterfeit drugs, valued at more than KSh40 million.   25 November 2015
Americas
Pharmaceutical company Pfizer has completed a $160 billion acquisition of generics company Allergan.   23 November 2015